Co-Author, Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer.
Clinical Cancer Research
Co-Author, Bisphosphonate Risks and Benefits: Finding a Balance.
Journal of Clinical Oncology
Co-Author, Are bisphosphonates ready for the adjuvant setting?
Co-Author, Pain in long-term breast cancer survivors: frequency, severity, and impact.
Co-Author, Kinetic analysis of 18F-fluoride PET images of breast cancer bone metastases.
Journal of Nuclear Medicine
Combination anastrozole and fulvestrant in metastatic breast cancer.
N. Engl. J. Med., Aug;367(5):435-44 (2012)
A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316).
Oncologist., 17(9):1180-90 (2012)
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.
Lancet Oncol., Jul;13(7):734-42 (2012)
Hypnosis for symptom management in women with breast cancer: a pilot study.
Int J Clin Exp Hypn., Apr;60(2):135-59 (2012)
Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430.
Oncologist., 17(2):179-87 (2012)
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.
J. Clin. Oncol., Dec;29(34):4491-7 (2011)
Can we predict who's at risk for developing bone metastases in breast cancer?
J. Clin. Oncol., Sep;29(27):3600-4 (2011)
How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer?
J. Clin. Oncol., Sep;29(26):3591-2; author reply 3592-3 (2011)
SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer.
Breast Cancer Res. Treat., Nov;130(1):123-31 (2011)
Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221).
Breast Cancer Res. Treat., Dec;130(3):993-1002 (2011)
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
Clin. Cancer Res., Jul;17(14):4799-805 (2011)
Axillary vs sentinel lymph node dissection for invasive breast cancer.
JAMA., Jun;305(22):2290; author reply 2290-1 (2011)
Breast cancer management in low resource countries (LRCs): consensus statement from the Breast Health Global Initiative.
Breast., Apr;20 Suppl 2:S3-11 (2011)
Problem solving for breast health care delivery in low and middle resource countries (LMCs): consensus statement from the Breast Health Global Initiative.
Breast., Apr;20 Suppl 2:S20-9 (2011)
PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.
Clin. Cancer Res., Apr;17(8):2400-9 (2011)
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.
J. Clin. Oncol., Feb;29(6):651-9 (2011)
Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012.
J. Clin. Oncol., Mar;29(8):1014-21 (2011)
Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer.
Clin. Breast Cancer., Dec;10(6):421-39 (2010)
Bisphosphonate risks and benefits: finding a balance.
J. Clin. Oncol., Nov;28(33):4873-6 (2010)
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.
J. Clin. Oncol., Oct;28(28):4307-15 (2010)
Are bisphosphonates ready for the adjuvant setting?
Oncology (Williston Park, N.Y.)., May;24(6):480, 485 (2010)
Pain in long-term breast cancer survivors: frequency, severity, and impact.
Pain Med., Jul;11(7):1099-106 (2010)
Metastasis and bone loss: advancing treatment and prevention.
Cancer Treat. Rev., Dec;36(8):615-20 (2010)
Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer.
Clin. Cancer Res., May;16(10):2803-10 (2010)
Kinetic analysis of 18F-fluoride PET images of breast cancer bone metastases.
J. Nucl. Med., Apr;51(4):521-7 (2010)
Breast cancer advocacy: changing perceptions.
Salud Publica Mex., 51 Suppl 2:s323-8 (2009)
Recommendations for research priorities in breast cancer by the coalition of cancer cooperative groups scientific leadership council: imaging and local therapy.
Breast Cancer Res. Treat., Apr;120(2):273-84 (2010)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Lancet Oncol., Jan;11(1):55-65 (2010)
Early detection of breast cancer: new biomarker tests on the horizon?
Mol Diagn Ther., Dec;13(6):349-57 (2009)
Neoadjuvant chemotherapy for locally advanced breast cancer.
Semin Radiat Oncol., Oct;19(4):222-8 (2009)
NCCN Task Force Report: Bone Health in Cancer Care.
J Natl Compr Canc Netw., Jun;7 Suppl 3:S1-32; quiz S33-5 (2009)
Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization.
Breast Cancer Res. Treat., Feb;119(3):511-27 (2010)
Adjuvant chemotherapy in older women with early-stage breast cancer.
N. Engl. J. Med., May;360(20):2055-65 (2009)
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
J. Clin. Oncol., Apr;27(10):1564-71 (2009)
Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.
J. Clin. Oncol., Sep;26(27):4449-57 (2008)
Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
Cancer Treat. Rev., 34 Suppl 1:S31-42 (2008)
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
J. Clin. Oncol., Feb;26(5):814-9 (2008)
Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions.
J. Clin. Oncol., Feb;26(5):696-7 (2008)
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
J. Clin. Oncol., Mar;26(8):1231-8 (2008)
Recruiting patients with breast cancer and their families to behavioral research in the post-HIPAA period.
Oncol Nurs Forum., Sep;34(5):1049-54 (2007)
Breast cancer 2004: Progress and promise on the clinical front.
Phys Med., 21 Suppl 1:2 (2006)
Bone density in breast cancer: when to intervene?
J. Clin. Oncol., Aug;25(22):3194-7 (2007)
Helping Her Heal: a pilot study of an educational counseling intervention for spouses of women with breast cancer.
Psychooncology., Feb;17(2):131-7 (2008)
Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623.
J. Clin. Oncol., May;25(13):1677-82 (2007)
Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
Breast Cancer Res. Treat., Sep;105(1):87-94 (2007)
Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.
J. Clin. Oncol., Jun;24(18):2793-9 (2006)
Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.
Clin. Breast Cancer., Jun;6(2):132-42 (2005)
Optimizing the treatment of metastatic breast cancer.
Breast Cancer Res. Treat., 89 Suppl 1:S9-S15 (2005)
Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival.
Cancer., Feb;103(4):680-8 (2005)
Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer.
J. Clin. Oncol., Jan;23(1):24-9 (2005)
Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC).
Am. J. Clin. Oncol., Aug;27(4):407-10 (2004)
HER-2 testing in breast cancer using parallel tissue-based methods.
JAMA., Apr;291(16):1972-7 (2004)
Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy.
J. Nucl. Med., Nov;44(11):1806-14 (2003)
Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment.
Cancer Immunol. Immunother., Jul;44(5):265-72 (1997)
Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.
J. Clin. Oncol., Apr;15(4):1395-400 (1997)